Chemical compounds

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Managed care, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Chemical compounds, Health sciences, Ketones, Pregnanes, Sterols, CDKL5 deficiency disorder, Ganaxolone, CDKL5, Allosteric modulator

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year and is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus.

Guidehouse Insights Report Forecasts a 16% Compound Annual Growth Rate through 2030 for the Global HVAC Market Using Low Global Warming Potential Refrigerants

Retrieved on: 
Tuesday, August 3, 2021
Other Energy, Other Retail, Utilities, Consumer electronics, Alternative energy, Energy, Technology, Residential Building & Real Estate, Environment, Construction & Property, Retail, Building Systems, Refrigerants, Heating, ventilation, and air conditioning, Chemistry, Chemical compounds, Physical sciences, Greenhouse gases, Industrial gases, Global warming potential, Natural refrigerant, Hydrofluoroolefin, Guidehouse Insights, Guidehouse, GUIDEHOUSE INSIGHTS, GUIDEHOUSE

A new report from Guidehouse Insights analyzes the global HVAC market and plans to phase out high global warming potential (GWP) refrigerants, with global market forecasts extending through 2030.

Key Points: 
  • A new report from Guidehouse Insights analyzes the global HVAC market and plans to phase out high global warming potential (GWP) refrigerants, with global market forecasts extending through 2030.
  • According to a new report from Guidehouse Insights, the global HVAC market using low GWP refrigerants is anticipated to be $34.1 billion in 2021, experiencing a compound annual growth rate (CAGR) of 16.2% from 2021 to 2030.
  • Nevertheless, regulation and policy are expected to transform the HVAC market from high GWP refrigerant applications to low GWP refrigerant applications, creating substantial new market opportunities.
  • The report, Low Global Warming Potential Refrigerants in HVAC , analyzes the global HVAC market including international treaties and national regulations for phasing out high GWP refrigerants, current technology trends including new refrigerant development, and industry trends.

CFC To Host Conference Call on Fiscal Year 2021 Financial Results

Retrieved on: 
Monday, August 2, 2021
Environmental issues, Ozone depletion, National Rural Utilities Cooperative Finance Corporation, Chemical compounds, Chlorofluorocarbon, Chemistry, U.S. Securities and Exchange Commission

DULLES, Va., Aug. 02, 2021 (GLOBE NEWSWIRE) -- The National Rural Utilities Cooperative Finance Corporation (CFC) will hold an investor conference call and webcast on Wednesday, August 4, at 11 a.m. Eastern Time.

Key Points: 
  • DULLES, Va., Aug. 02, 2021 (GLOBE NEWSWIRE) -- The National Rural Utilities Cooperative Finance Corporation (CFC) will hold an investor conference call and webcast on Wednesday, August 4, at 11 a.m. Eastern Time.
  • CFC CEO Andrew Don will provide a business update and CFC Senior Vice President and CFO Ling Wang will review CFCsfiscal year 2021 financial results.
  • There are two ways to access the event:
    Visit CFCs investor Webcasts & Presentations page to join the webcast.
  • CFCs Form 10-K for the period ended May 31, 2021, has been filed with the U.S. Securities and Exchange Commission (SEC).

G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer

Retrieved on: 
Monday, August 2, 2021
Organic compounds, Chemical compounds, G1 Therapeutics, Chemistry, Trilaciclib

RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its Chief Commercial Officer (CCO).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its Chief Commercial Officer (CCO).
  • As we continue to evolve as a commercial company and execute on the launch of COSELA (trilaciclib), we are excited to announce the addition of Andrew to the G1 Therapeutics Executive Team, said Jack Bailey, Chief Executive Officer of G1 Therapeutics.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

LianBio Appoints Pascal Qian as General Manager of China

Retrieved on: 
Monday, August 2, 2021
Health, Biotechnology, Chemical compounds, Organic compounds, Aminopyridines, Thioethers, Chloroarenes, Specialty drugs, Protein kinase inhibitors, Palbociclib, Sunitinib, Axitinib, Crizotinib, Qian

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.

Key Points: 
  • LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.
  • Mr. Qian has extensive experience launching products in China, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair.
  • He has also led new product development initiatives in China for multiple globally developed drugs, including crizotinib, axitinib and palbociclib.
  • Mr. Qian most recently served as the Vice President, Head of Oncology Business Unit, at Lilly China.

Chevron Introduces Delo® Syn ATF 668, a Fully Synthetic Transmission Fluid Approved and Licensed by Allison Transmission® for Transmissions Requiring TES 668™

Retrieved on: 
Monday, August 2, 2021
Public transport, Trucking, Aftermarket, Automotive, General Automotive, Transport, Chemicals, Plastics, Manufacturing, Fleet management, Hydraulic fluids, Mechanical engineering, Chemical compounds, Hydraulics, Transmission, ATF, Allison, Matter, Motor oils, Oils, Automatic transmission fluid

Chevron Products Company, a division of Chevron U.S.A. Inc., today announced the launch of Delo Syn ATF 668, a fully synthetic transmission fluid specifically engineered for Allison heavy duty automatic truck and bus transmissions.

Key Points: 
  • Chevron Products Company, a division of Chevron U.S.A. Inc., today announced the launch of Delo Syn ATF 668, a fully synthetic transmission fluid specifically engineered for Allison heavy duty automatic truck and bus transmissions.
  • Engineered for longer service life, improved transmission performance, optimal fluid performance and improved clutch operation, Delo Syn ATF 668 is approved and licensed by Allison for transmissions requiring TES 668 and is backwards compatible with TES 389 and TES 295.
  • Manufactured with synthetic base oils and state-of-the-art additives, it is a next-generation fluid for modern Allison transmissions, building and improving on the proven performance of TES 389 and TES 295 fluids.
  • We developed Chevron Delo Syn ATF 668 to meet the needs of businesses and municipalities who operate fleets that traditionally rely on vehicles with Allison transmissions, said Jason Gerig, Chevron Americas Commercial On & Off Highway Sector Manager.

Semiconductor Market in East Asia to grow by USD 84.41 billion|Technavio

Retrieved on: 
Monday, August 2, 2021
Chemistry, Physical sciences, Chemical compounds, Inorganic compounds, Bazaars, Marketplace, Gallium arsenide, SEMI, Gallium nitride, National Semiconductor

To gain access to detailed market landscape, vendor analysis, and future trends impacting the growth of the market, download a sample:

Key Points: 
  • To gain access to detailed market landscape, vendor analysis, and future trends impacting the growth of the market, download a sample:
    Semiconductor Market in East Asia 2021-2025: Vendor Analysis and Scope
    To help businesses improve their market position, the semiconductor market in East Asia provides a detailed analysis of around 25 vendors operating in the market.
  • The report also covers the following areas:
    The growth of the consumer electronics market will offer immense growth opportunities.
  • Backed with competitive intelligence and benchmarking, our research reports on the semiconductor market in East Asia are designed to provide entry support, customer profile & M&As as well as go-to-market strategy support.
  • Semiconductor Market in East Asia 2021-2025: Key Highlights
    Related Reports on Information Technology Include:
    Global Compound Semiconductor Market- The compound semiconductor market is segmented by end-user (consumer electronics, communications, defense and aerospace, automotive, and others), type (GaAs, GaN, SiC, and others), and geography (APAC, North America, Europe, South America, and MEA).

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

Retrieved on: 
Friday, July 30, 2021
Organic compounds, Epidermal growth factor receptor, Oncogenes, KRAS, Chemical compounds, Quinazolines, Cancer, Amines, Chloroarenes, Gefitinib, Icotinib

Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.

Key Points: 
  • Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.
  • The published data supported the Investigational New Drug application for the ongoing AFM24 Phase 1/2a dose escalation study.
  • The published data were the basis for the Investigational New Drug (IND) clearance for Affimeds ongoing Phase 1/2a study with AFM24 monotherapy in patients with EGFR expressing solid tumors.
  • AFM24 is effective against many EGFR-positivetumorcells, regardless of EGFR expression level and KRAS/BRAF mutational status within in vitro studies.

LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

Retrieved on: 
Thursday, July 29, 2021
Chemical compounds, Health care, Health sciences, Muscarinic antagonists, Boehringer Ingelheim, Bromides, Epoxides, Thiophenes, Tiotropium bromide, Abbreviated New Drug Application, Inhaler

PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.

Key Points: 
  • PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.
  • U.S. sales of Spiriva Handihaler were $1.5 billion for the 12 months ending May, 2021 according to IQVIA, although actual generic market values are expected to be lower.
  • "With generic Spiriva Handihaler, our strategic relationship with Respirent now includes three inhaler products, each of which has the potential to be a meaningful contributor to our company's financial performance.
  • The generic Spiriva Handihaler product is currently in development and tracking to Abbreviated New Drug Application (ANDA) submission in 2023."

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Rocket, 360 DigiTech, and Piedmont Lithium and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 29, 2021
Chemistry, Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Euphoriants, Sufentanil, Fentanyl, Lithium

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • OnFebruary 16, 2021, AcelRx disclosed that, onFebruary 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA.
  • For more information on the Piedmont Lithium class action go to: https://bespc.com/cases/PLL
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.